S. Olson

发表

Pharmacokinetics of Quinapril and its Active Metabolite Quinaprilat During Continuous Ambulatory Peritoneal Dialysis

R. Swartz, B. Starmann, A. M. Horvath, 1990, Journal of clinical pharmacology.

Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

S. Olson, P. Siedlik, B. Yang, 1999, Journal of clinical pharmacology.

A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

M. Hidalgo, D. Ryan, B. Arun, 2006, Clinical Cancer Research.

APhase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combinationwith Docetaxel in Patients with Advanced Solid Tumors

M. Hidalgo, D. Ryan, B. Arun, 2006 .

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

G. Bepler, M. Fishman, P. Munster, 2006, Clinical Cancer Research.

Controversy II: Bioequivalence as an Indicator of Therapeutic Equivalence: Modeling the Theoretic Influence of Bioinequivalence on Single‐Dose Drug Effect

J. Ferry, W. Colburn, S. Olson, 1987, Journal of clinical pharmacology.

Effect of food and tablet age on relative bioavailability and pharmacodynamics of two tolbutamide products.

S. Olson, E. Antal, J. Ayres, 1985, Journal of pharmaceutical sciences.

Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin

S. Olson, R. Stern, B-B Yang, 1997, Journal of clinical pharmacology.

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.

R. Schilsky, M. Ratain, N. Vogelzang, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase1Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patientswith Refractory Cancer

D. Shin, N. Senzer, J. Nemunaitis, 2005 .

Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat).

J. Ferry, W. Colburn, A. M. Horvath, 1990, Biopharmaceutics & drug disposition.

Quinapril: Overview of preclinical data

S. Olson, D. Taylor, H. R. Kaplan, 1990, Clinical cardiology.

Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy.

S. Olson, A. Goldberg, J. Froelich, 1987, The American journal of cardiology.

The Pharmacokinetics of Quinapril and Its Active Metabolite, Quinaprilat, in Patients with Various Degrees of Renal Function

A. M. Horvath, S. Olson, E. Posvar, 1992, Journal of clinical pharmacology.

Pharmacokinetics of Quinapril and Its Active Metabolite, Quinaprilat, in Patients on Chronic Hemodialysis

R. Kohli, A. Sedman, A. M. Horvath, 1990, Journal of clinical pharmacology.

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

A. Tolcher, P. LoRusso, A. Patnaik, 2004, Clinical Cancer Research.

The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.

A. Sedman, A. Richards, H. Ikram, 1994, British journal of clinical pharmacology.

Pharmacodynamics and Pharmacokinetic‐Pharmacodynamic Relationships of Atorvastatin, an HMG‐CoA Reductase Inhibitor

S. Olson, B. Yang, R. Stern, 2000, Journal of clinical pharmacology.

Quinapril—A Preclinical Review of the Pharmacology, Pharmacokinetics, and Toxicology

S. Olson, D. Taylor, David G. Taylor, 1989, Angiology.

Disposition of quinapril and quinaprilat in the isolated perfused rat kidney

S. Olson, David E. Smith, A. Kugler, 1995, Journal of Pharmacokinetics and Biopharmaceutics.

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

J. Nemunaitis, G. Netto, D. Kirn, 2001, Gene Therapy.

Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: Effect of organic anions and cations

S. Olson, David E. Smith, A. Kugler, 1996, Journal of Pharmacokinetics and Biopharmaceutics.

Phase I Study of Oral CI‐994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer

J. Nemunaitis, R. Mennel, S. Olson, 2003, Cancer journal.

Determination of quinapril and quinaprilat by high-performance liquid chromatography with radiochemical detection, coupled to liquid scintillation counting spectrometry.

S. Olson, A. Kugler, D. Smith, 1995, Journal of chromatography. B, Biomedical applications.

The Clinical Pharmacokinetics of Quinapril

P. Welling, W. Colburn, A. Sedman, 1989, Angiology.

Phase I Study of Oral CI-994 in Combination with Carboplatin and Paclitaxel in the Treatment of Patients with Advanced Solid Tumors

J. Nemunaitis, A. Kraker, S. Olson, 2004, Cancer investigation.

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Ralph G Zinner, Dong M Shin, D. Shin, 2005, Clinical Cancer Research.

Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Xin Huang, Ralph G. Zinner, Peter F. Lenehan, 2007, Clinical Cancer Research.

Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients

Qihong Huang, T. Asselah, D. Tweedie, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors.

D. Sullivan, C. Garrett, G. Simon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.

T. Annesley, S. Olson, J. Koup, 1998, Clinical chemistry.

LC/MS/MS quantitation of an anti-cancer drug in human plasma using a solid-phase extraction workstation: application to population pharmacokinetics.

S. Olson, L. Cohen, D. T. Rossi, 2001, Journal of pharmaceutical and biomedical analysis.

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

P. Ellis, J. Hamm, P. Lenehan, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overview of Quinapril, A New ACE Inhibitor

A. Sedman, S. Olson, L. Knapp, 1990, Journal of cardiovascular pharmacology.

Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine

S. Olson, R. Stern, J. Smithers, 1998, Journal of clinical pharmacology.

The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.

K. Lynn, S. Olson, R. Robson, 1990, British journal of clinical pharmacology.

The pharmacokinetics of angiotensin converting enzyme inhibitors in patients with renal impairment.

K. Lynn, S. Olson, R. Robson, 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

A population pharmacokinetic profile of imazodan in congestive heart failure patients

S. Olson, 1991, Journal of Pharmacokinetics and Biopharmaceutics.